Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
QURE · Nasdaq · United States · Pharmaceutical Preparations
In shortuniQure N.V. is loss-making, burns cash and holds more cash than debt, with revenue shrinking (−40.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1151.4% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -1236.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -207.1% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -58.9% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 10.43× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.25× | 97/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -2.99× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -1.71 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -1108.2% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 598.3% | 0/100 |
| Operating margin volatility | 753.6% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -46.7% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 524 | 106 | 16 | 27 | 16 |
| Cost of revenue | 25 | 1.3 | 0.1 | 1.3 | 1.7 |
| Gross profit | 499 | 105 | 16 | 26 | 14 |
| Research & development | 144 | 198 | 215 | 144 | 141 |
| Selling, general & admin | 56 | 55 | 75 | 53 | 65 |
| Operating income | 311 | (143) | (283) | (184) | (185) |
| Interest expense | 7.5 | 12 | 42 | 64 | 62 |
| Pre-tax income | 333 | (128) | (307) | (237) | (193) |
| Income tax | 3.2 | (1.5) | 1.9 | 2.4 | 5.6 |
| Net income | 330 | (127) | (308) | (240) | (199) |
| Diluted EPS | $7.04 | −$2.71 | −$6.47 | −$4.92 | −$3.46 |
| Diluted shares (millions) | 47 | 47 | 48 | 49 | 58 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 7 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 7 quarters of uniQure N.V. are included in the Investor plan. Try free for 7 days →
−1.71 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated May 5, 2026